Indoco Remedies Shares Gain Focus Following EU GMP Certification for Baddi Facility

Indoco Remedies Receives EU GMP Certification for Baddi Manufacturing Facility

On May 29, the share price of Indoco Remedies will remain in focus after the pharmaceutical company received the European Union Good Manufacturing Practice (EU GMP) certification from the German Health Authority (Berlin) for its manufacturing facility in Baddi, Himachal Pradesh.

The certification has been granted for the company's Oral Solid Dosage (OSD) manufacturing facility (Plant III). The inspection was conducted between April 22 and April 27, 2026. This certification confirms that the facility complies with Good Manufacturing Practice requirements as referred to in the EC Directive.

Market analysts will be keeping a close eye on the company's performance following this development. Indoco Remedies' Managing Director, Aditi Panandikar, has stated that the EU GMP certification for their formulations manufacturing plant is a testament to their commitment to delivering high-quality products to patients across the globe.

Read also: Wockhardt Secures Second US Approval for New Drug, Eyes Commercial Viability

This certification marks the second EU GMP certification received by the company's Baddi facility, following the certification of its solid oral dosage manufacturing facility (Unit I) by the Malta Medicines Authority earlier this month.

As of the previous trading session, Indoco Remedies shares closed at Rs 203.75, higher by Rs 9.90 or 5.11 percent. The stock touched a 52-week high of Rs 348.10 on July 17, 2025, and a 52-week low of Rs 163.70 on March 30, 2026.

At current levels, the stock is trading 41.47 percent below its 52-week high and 24.47 percent above its 52-week low. The company's market capitalisation stands at Rs 1,880.69 crore.

Read also: US FDA Approves Wockhardt's Zaynich for Treatment of Complicated Urinary Tract Infections in Adults